Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data
Switching to IL-17Ai vs. cycling to another TNFi provided similar or numerically improved outcomes in both cohorts, underscoring the importance of considering alternative mechanisms of action for these patients.
Authors
- Marcus Ngantcha
- Andris Kronbergs
- Elsie Grace
- Maya Marchese
- Philip J. Mease
- Jessica A. Walsh
- Nicole Middaugh
- Alexis Ogdie
- Natalia Bello
Institutions
- Eli Lilly (United States) (US)
- Providence College (US)
- University of Washington (US)
- University of Utah (US)
- VA Salt Lake City Healthcare System (US)
- Swedish Medical Center (US)
- Navitas Systems (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2026-03-12
- DOI
- https://doi.org/10.1007/s12325-026-03531-5
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Celgene
- LEO Pharma
- Genentech
- Chugai Pharmaceutical
- Janssen Pharmaceuticals